Drug Type Small molecule drug |
Synonyms HR 20033, HR-20033, HR20033 + [1] |
Target |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (29 Dec 2023), |
Regulation- |
Molecular FormulaC22H24ClFO7 |
InChIKeyHYTPDMFFHVZBOR-VNXMGFANSA-N |
CAS Registry1623804-44-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | CN | 29 Dec 2023 |
Corporate Publications Manual | Phase 3 | - | hpsbrqdgiq(fipcbrsiuy) = nanbhuqbub sxxcngfitj (jgocosgttv ) View more | Positive | 08 Jan 2024 | ||
hpsbrqdgiq(fipcbrsiuy) = glsbzvxzbp sxxcngfitj (jgocosgttv ) View more |